Actualizaciones regulatorias27 sept 2026•1 min de lectura

FDA Approves ANDA077076 for Lorazepam Injectable Products

Por el equipo de PharmaCountry

FDA approved ANDA077076 submitted by Bedford for Lorazepam injectable products (2 mg/mL and 4 mg/mL), both listed as discontinued.

The U.S. Food and Drug Administration has approved application ANDA077076, submitted by Bedford, for Lorazepam injectable products. The approval covers two injectable dosage strengths: 2 mg/mL (product number 001) and 4 mg/mL (product number 002). Both products are currently marked as discontinued in the FDA’s records. The original submission (submission number 1) received approval on July 13, 2005.

Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov

Temas:#Lorazepam #Injectable #ANDA #FDA approval #Bedford